goldennet

JAN.11
2024

Congratulations! Genomics is proud to announce its exclusive distributorship for Thermo Fisher’s Applied Biosystems™ SeqStudio™ Genetic Analyzer in Taiwan's hospital channels.

Hands-on with the SeqStudio Genetic Analyzer | Demo Video (youtube.com)


感謝Thermo Fisher原廠對於基龍米克斯能力的信任與實力的肯定;基龍米克斯擁有業界最豐富的定序服務經驗,且為國內最大的商業基因體服務公司,更有多項大型專案的執行經驗,在台灣生技界貢獻良多。因此,基龍米克斯希望透過這次機會,以用一個過來人的身分,有效地協助同業或醫院、醫檢單位建置相關服務,滿足未來因NGS健保政策而新增的LDTs申請需求!

SeqStudio™ Genetic Analyzer

test

簡介:

隨著科技蓬勃發展,諸多技術也在推陳出新為生命解開未知的核酸密碼,而作為黃金法則的Sanger定序依舊是根本核心。有別於以往其他機型的高昂價格與龐大體積,Applied Biosystems™ SeqStudio™ Genetic Analyzer承載著現今趨勢及潮流,實現體積精簡化但兼具高效能的毛細管電泳儀,在一盤實驗中可彈性設定區分Sanger sequencing (桑格定序)和Fragment analysis (片段分析)的上樣模式。配備卡匣(Cartridge)系統及自動運行前校正功能,將實驗前的繁瑣作業簡化在一鍵啟動之間。結合雲端平台的便利性,使用者可進行遠端儀器監控或數據上傳共享,這些優勢無疑賦予了SeqStudio Genetic Analyzer成為市場上最具競爭力的定序設備。

因應未來對於實驗室自行研發檢驗技術(Laboratory developed tests, LDTs)的認證需求,基龍米克斯與定序設備大廠Thermo Fisher Scientific實現雙強聯手,向各醫療單位推廣SeqStudio Genetic Analyzer的建置,並運用臺灣在地定序服務二十多餘年的豐富經驗,協助各大醫院及醫事檢定所等單位架設符合LDTs認證標準的實驗室,希冀於實現定序設備與技術的普及化,為人類未來福祉帶來全新曙光。


儀器特點:

◆ 預設卡匣縮短前置準備步驟,降低人為疏失可能性

◆ 人性化操作介面與互動式觸控螢幕,簡單無痛好上手

◆ 單次運行可同時進行定序及片段分析,大幅提高效率及應用層面

◆ 自動化運行前校正與耗材追蹤機制,支援遠端監測及數據自動備份功能


技術優勢:

使用便利,卡匣整合實驗所需的試劑

搭配All-in-one Cartridge (卡匣系統),已內建毛細管、POP-1 (universal polymer)與陰極緩衝液,只需將DNA樣本放入96孔盤或8-strip tube中,按下開關即刻啟動。儀器可追蹤試劑上的FRID標籤,進行消耗量紀錄與效期管理;也配備運行前自動校正功能,大幅簡化工作流程。


效率提升,同時進行定序與片段分析

優化的程式設計可支援在單次運行中,同時進行Sanger定序及片段分析,縮短不同目的實驗的操作流程。此外SeqStudio Genetic Analyzer既能使用Thermo毛細管電泳相關的試劑,也兼容其他品牌的分生檢測套組,如MRC Holland的Multiplex Ligation-dependent Probe Amplification (MLPA) 等,拓展應用層面的多元性。


雲端管理,遠端監控與數據整合共享

運用電腦或手機上的專屬程式,使用者可進行遠端監控或遙控操作,及時追蹤實驗進度;儀器也結合現今雲端平台的便利性,除具備自動備份的功能外,也能在雲端分析數據或分享實驗結果。


分析應用:

Sanger sequencing (桑格定序):

Resequencing, next-generation sequencing (NGS) confirmation, indel analysis, heterozygote detection, minor variant detection, microbial identification, genome editing verification.

Fragment analysis (片段分析):

Microsatellite analysis (compatible with MLPA™ technology), Applied Biosystems™ SNaPshot™ applications and cell line authentication.


儀器規格:

Other News

Other News

Genomics (4195) Signs Exclusive Sales Agency Contract with Thermo Fisher Scientific

Considering Genomics’ continuous expansion and partnerships in areas such as cell therapy, exosomes, and CDMO, along with plans for new facilities starting this year, there will be a significant demand for laboratory equipment. Therefore, since the second half of 2023, we have actively pursued an exclusive sales agency for certain products of Thermo Fisher Scientific's LPD series in Taiwan. We are delighted to have successfully completed this signing, further deepening our partnership.

MAR.13
2024

Genomics demonstrate the CDMO Milestone Outcomes at the BIO Asia-Taiwan

The “2023 BIO Asia–Taiwan International Conference and Exhibition” officially opens today (27th). Genomics BioSci & Tech. Co. Ltd., Taiwan’s leading genetic sequencing company (hereafter referred to as “Genomics”, stock code: 4195), announced that the company will demonstrate the milestone outcomes of the company’s transformation progress, showcasing the results of the PIC/S GMP nucleic acid and polypeptide pilot plant at the Expo’s CDMO (Contract Development & Manufacturing Service) Exhibition Area. The company not only has successfully upgraded the nucleic acid synthesis services for scientific research into provision of raw materials for high-grade detection probe kits and nucleic medications, but will also form strategic alliances with partners to jointly develop new products in the future, expanding clinical applications and exploring new international markets. The company seeks to cross into the fields of precision gene therapy and cancer therapy by offering integrated service solutions and maintaining key position in the supply chain of nucleic acid industry.

JUL.27
2023

Top

Contact

Contact Us

Contact

Contact Us

Search

Search Entire Website

Search for products or news